Evidence map›Paper›PMID 40128995›Full record

ArticleInternal medicine (Tokyo, Japan)2025

New-onset Fulminant Type 1 Diabetes Following COVID-19 Vaccination.

Takaaki Shigematsu, Yu Yamaguchi, Takeo Watanabe, Kazutaka Tsujimoto, Fuminori Sato, Tetsuya Yamada, Motoyoshi Tsujino

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Takaaki ShigematsuFraternity Memorial Hospital, Department of Diabetology and Metabolism, Japan.
Yu YamaguchiFraternity Memorial Hospital, Department of Diabetology and Metabolism, Japan.
Takeo WatanabeFraternity Memorial Hospital, Department of Diabetology and Metabolism, Japan.
Kazutaka TsujimotoDepartment of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Japan.
Fuminori SatoTokyo Metropolitan Tama Medical Center, Department of Endocrinology and Metabolism, Japan.
Tetsuya YamadaDepartment of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Japan.
Motoyoshi TsujinoTokyo Metropolitan Tama Medical Center, Department of Endocrinology and Metabolism, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 31-year-old Japanese man was admitted with a slight fever and epigastric pain. He had received his third Moderna Coronavirus disease 2019 (COVID-19) vaccine dose (Spikevax, mRNA-1273) 16 days before his visit. His serum amylase level was elevated, and computed tomography found pancreatic enlargement. Acute pancreatitis was diagnosed, and the patient was treated with fasting and intravenous fluids. However, on day 3 of hospitalization, his blood glucose level had increased to 320 mg/dL. His serum and urinary C-peptide were remarkably low (≤0.03 ng/mL and ≤0.6 μg/day, respectively). Finally, fulminant type 1 diabetes mellitus caused by the COVID-19 mRNA vaccine was diagnosed.

Indexed as

COVID-19COVID-19 VaccinesDiabetes Mellitus, Type 1Vaccination2019-nCoV Vaccine mRNA-1273AdultHumansMalePancreatitisSARS-CoV-22019-nCoV Vaccine mRNA-1273COVID-19 Vaccinesautoimmune diseaseCOVID-19 RNA vaccinefulminant type 1 diabetes mellituspancreatic enlargement

Identifiers

PMID40128995
PMCPMC12222934

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.